Sanara MedTech Inc. (SMTI) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

team with the expertise necessary to achieve our mission of improving clinical outcomes and reducing healthcare expenditures in the surgical market. I'm proud of the level of talent we've been able to attract in recent years. Though we've made impressive progress, I believe we have opportunities to continue evolving as an organization. I'm confident in our team's ability to achieve the next stage of sustainable growth and development as we continue to expand our share of the large untapped market opportunity the products address. Now, I'd like to address the announcement we made yesterday regarding Tissue Health Plus and provide some additional context on this important strategic decision. I'll begin with some background for those less familiar. In parallel with developing and establishing THP, Sonera has been focused over the last two years on identifying and engaging with potential strategic and financial partners to invest in and assist in the execution of this business. At the beginning of the third quarter, we initiated a formal process of evaluating strategic alternatives for THP, which we announced on our second quarter call in August. We engaged an external strategic advisor to assist in this process as we explored a range of options with a goal of maximizing shareholder value. Together with our external strategic advisor, we performed a market check and explored a range of strategic alternatives during the third quarter. This formal process ultimately did not result in finding a partner to assume significant responsibility for this investment or surface a viable option to monetize our THP asset. After concluding this process, our management team and board of directors determined that the most appropriate course of action was to cease operations of THP. which...